Bladder cancer: translating molecular genetic insights into clinical practice.
about
Understanding the molecular pathogenesis and prognostics of bladder cancer: an overviewCell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomenaEmerging critical role of molecular testing in diagnostic genitourinary pathologyDiagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysisPrognostic significance of mucin expression in urothelial bladder cancer.Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value.Molecular subtyping of bladder cancer using Kohonen self-organizing mapsPathobiology and chemoprevention of bladder cancerPrognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder.Epigenetic alterations in bladder cancer and their potential clinical implications.An integrated method for the identification of novel genes related to oral cancerCorrelation and Significance of Urinary Soluble Fas and Vascular Endothelial Growth Factor in Bladder Urothelial CancerSPOCK1 Overexpression Confers a Poor Prognosis in Urothelial Carcinoma.TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewalMolecular signatures in urologic tumors.TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphismDownregulation of RNF128 Predicts Progression and Poor Prognosis in Patients with Urothelial Carcinoma of the Upper Tract and Urinary Bladder.Detection of loss of heterozygosity in patients with urinary bladder carcinoma: neoplastic tissue vs. urine sediment cells.Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma.Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years.Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-upDiagnosis and management of urothelial carcinoma of the bladder.Moving forward in bladder cancer detection and diagnosis: the role of epigenetic biomarkers.Alterations of DNA methylome in human bladder cancer.Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.Predictive markers in bladder cancer: do we have molecular markers ready for clinical use?Present and future of personalized medicine in adult genitourinary tumors.Molecular markers in bladder cancer: Novel research frontiers.Cytotoxic and toxicogenomic effects of silibinin in bladder cancer cells with different TP53 status.MiR-126 regulates proliferation and invasion in the bladder cancer BLS cell line by targeting the PIK3R2-mediated PI3K/Akt signaling pathway.MRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells.Functional and molecular characterization of kinin B1 and B 2 receptors in human bladder cancer: implication of the PI3Kγ pathway.Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes.Detection of Copy Number Imbalance in Canine Urothelial Carcinoma With Droplet Digital Polymerase Chain Reaction.Immunocytochemical staining for p53 and Ki-67 helps to characterise urothelial cells in urine cytology.TRAF6 expression is associated with poorer prognosis and high recurrence in urothelial bladder cancer.Roles of Signal Transducer Pathways in Investigation of Biopsies from Patients with Bladder TumorsExpression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status.Aberrant deleted in liver cancer-1 expression is associated with tumor metastasis and poor prognosis in urothelial carcinoma.Combined use of fluorescence cystoscopy and cross-polarization OCT for diagnosis of bladder cancer and correlation with immunohistochemical markers.
P2860
Q26752921-A5C7F2DA-4457-4F07-9E20-02CDEE384052Q26860953-C09FB0EA-33A2-4F63-9F3C-3A07EB366D73Q27021371-F918EECB-6581-4BF2-915F-91F7318C9A8DQ33982159-F6D6FA47-EE94-4148-8A8C-02166EEB19A3Q34121441-6E58890F-16F0-4FA9-BE7D-EE72697C1632Q34674350-C7180F75-5044-41C3-86E3-04F6E1AF15DCQ34998489-15C9B44C-B4AA-4093-BCF7-2D25763B05CFQ35219328-8B2C17C2-81E0-4EB7-A108-23141317C365Q35653741-3FD7ACD6-0D28-4941-8DAC-93FDF881009BQ36095721-3C82676B-B254-45BF-8FD6-9A9D8CD5FE8FQ36338202-6F2E85D5-649C-4FD5-BFDE-DD69EBDEB9FCQ36422922-1BA454CF-4E5C-4950-B256-70CBB89A6848Q36567906-1349ABF5-8B0E-49A8-B2C6-97DA9DDECB26Q36762656-1666134C-18CC-4422-A44A-26D52CDE59D9Q37225156-4DDE4360-E40D-4865-98F5-0416EB6085ADQ37256055-DC981AC9-8443-4AB5-9EBF-4B2E36C51021Q37514045-9D1FDC87-2D4B-4AC0-AC2D-6AC2FF58D405Q37579068-1070AC13-9525-4054-8B51-4C03278230C0Q37653128-71E70D1D-E34A-45BC-9118-C62619A2F80EQ37675922-61445E70-05C9-4EC0-A06D-14AF2657AAE8Q37687183-B4AF7E7B-2116-4E6E-BB14-A32F5E5928B6Q37874887-927EE5EC-E592-4242-8DEB-EC8161B20FA2Q38068225-15B48F78-716C-405C-9673-ADA664D5DDE2Q38131409-7BABE10E-2D3F-43FE-8DD9-B5B72BEDB852Q38155201-48376DC8-33A1-42B4-8F5C-445FF1927152Q38230912-77564EB3-4F04-4AE0-8DBA-50F3973C966FQ38465841-18D25548-385D-444B-B54E-E1717C31A3F5Q38520403-1A789467-D8BD-499B-82F2-27DB56D01087Q38715263-CAF20D40-A185-4DF5-8C7F-1E58ACC58E4BQ38748901-4BE79192-DE4A-4791-B86B-C9E93751BB4DQ39013393-505379CF-D895-49AE-A738-D4A5F7AFB3BEQ39229824-DA6477A2-9168-445C-B4A2-3DA07851873EQ39262247-7AF85F54-B509-4834-BB3E-AB97E294C4CBQ40331022-EEEC586E-84A2-4E09-BD2B-2BFCA4893553Q40462675-28DB83B1-DE97-4880-949A-9D0632B7E64CQ41145355-B2ACE096-B929-4374-B68C-7C2E27DB0E7BQ41461442-D281E818-E0CB-4D28-A727-0B0B4E331F55Q41621271-100918EB-B02D-4E9B-B5A3-7773B83FED22Q43708178-49EFF14C-EC48-4D63-8F9A-5571B0CA4CD6Q43888972-5B1B6FDB-C82E-4325-A6A8-C594838BBE98
P2860
Bladder cancer: translating molecular genetic insights into clinical practice.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Bladder cancer: translating molecular genetic insights into clinical practice.
@en
Bladder cancer: translating molecular genetic insights into clinical practice.
@nl
type
label
Bladder cancer: translating molecular genetic insights into clinical practice.
@en
Bladder cancer: translating molecular genetic insights into clinical practice.
@nl
prefLabel
Bladder cancer: translating molecular genetic insights into clinical practice.
@en
Bladder cancer: translating molecular genetic insights into clinical practice.
@nl
P2093
P1433
P1476
Bladder cancer: translating molecular genetic insights into clinical practice.
@en
P2093
Antonio Lopez-Beltran
Gregory T MacLennan
Liang Cheng
Shaobo Zhang
P304
P356
10.1016/J.HUMPATH.2010.07.007
P407
P577
2010-11-24T00:00:00Z